Renin-angiotensin-system-acting agents - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.29 [0.51, 3.26]< 10%1 study (1/-)29.5 %NAnot evaluable crucial-
death or transfer to ICU 0.57 [0.18, 1.79]< 10%1 study (1/-)83.3 %NAnot evaluable crucial-
deaths 0.75 [0.43, 1.30]< 10%5 studies (5/-)84.6 %lowserious highcrucial-
hospital discharge 1.17 [0.35, 3.84]> 188%2 studies (2/-)59.9 %some concernnot evaluable moderateimportant-
hospitalization 1.63 [0.94, 2.85]< 10%1 study (1/-)4.2 %NAnot evaluable important-
mechanical ventilation 1.23 [0.82, 1.83]< 10%3 studies (3/-)16.1 %some concernnot evaluable moderateimportant-
ICU admission 0.80 [0.40, 1.60]< 10%2 studies (2/-)73.9 %lownot evaluable highnon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.